VivaChek

Hangzhou, China Founded: 2013 • Age: 13 yrs
VivaChek is engaged in developing point-of-care testing solutions.

About VivaChek

VivaChek is a Healthcare company based in Hangzhou (China) founded in 2013. VivaChek is engaged in developing point-of-care testing solutions. It operates on a Direct-to-Consumer (D2C) and HealthTech model. VivaChek has raised $14.21 million across 1 funding round from investors including UMC Capital. VivaChek offers products and services including VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit. Its focus areas include Medical Devices and Point-of-Care Testing. Its legal entity in India is 杭州微策生物技术股份有限公司 (U99999MH1977PLC010754).

Company details

VivaChek, based in Hangzhou, China, is focused on the research, development, production, and sales of point-of-care testing (POCT) products. The company is dedicated to building an ecosystem of chronic disease management, rapid diagnostics, and digital healthcare. Solutions are provided in sectors such as blood glucose monitoring, uric acid analysis, and infectious disease detection. The aim is to become a globally trusted provider of smart POCT solutions, making health management accessible to all.

Key Metrics
  • Total Equity Funding
    $14.21M (USD)

    in 1 rounds

  • Latest Funding Round
    $14.21M (USD), Series C

    Dec 2019

  • Investors

Products & Services of VivaChek

VivaChek offers a comprehensive portfolio of products and services, including VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit.

VivaChek Blood Glucose Meter
Medical Devices

Blood glucose levels are monitored using this device.

VivaChek Uric Acid Analyzer
Medical Devices

Uric acid levels are measured with this analyzer.

VivaChek COVID Antigen Test Kit
Diagnostic Kits

COVID-19 antigens are detected using this test kit.

Funding Insights of VivaChek

VivaChek has successfully raised a total of $14.21M through 1 strategic funding round. The most recent funding activity was a Series C round of $14.21 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $14.21M
  • Total Rounds 1
  • Last Round Series C — $14.21M
  • First Round $14.21M

    (Dec 2019)

  • Investors Count 1

All 1 funding rounds of VivaChek with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2019$14.21MSeries C–UMC Capital
–
Valuation history

1 investors in total: 1 institutional.

Investors in VivaChek

VivaChek has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include UMC Capital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Semiconductors and diverse sectors are targeted by corporate-backed VC investments.
umccapital.comTaipei, Taiwan
Premium access

Investor details for VivaChek

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of VivaChek

2 dated milestones of VivaChek across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded VivaChek is founded.
  2. Funding First funding round of $14.2M.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vivachek

Premium access

Complete news archive for VivaChek

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about VivaChek

VivaChek was founded in 2013 and raised its 1st funding round 6 years after it was founded.

VivaChek is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.

VivaChek is a funded company, having raised a total of $14.21M across 1 funding round to date. The company's 1st funding round was a Series C of $14.21M, raised on Dec 2019.

VivaChek, based in Hangzhou, China, is focused on the research, development, production, and sales of point-of-care testing (POCT) products. The company is dedicated to building an ecosystem of chronic disease management, rapid diagnostics, and digital healthcare. Solutions are provided in sectors such as blood glucose monitoring, uric acid analysis, and infectious disease detection. The aim is to become a globally trusted provider of smart POCT solutions, making health management accessible to all.

VivaChek offers VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit.

VivaChek has 1 investor. Key investors include UMC Capital.

VivaChek operates through ,.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available